The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study

The efficacy and safety of a novel PD‐1/CTLA‐4 bispecific antibody cadonilimab (AK104) in advanced non‐small cell lung cancer: A multicenter retrospective observational study

Abstract Background For patients with advanced non‐small cell lung cancer (NSCLC) who have received frontline immunochemotherapy, subsequent treatment options are limited. As the first dual programmed cell death‐1 (PD‐1)/cytotoxic T lymphocyte‐associated antigen‐4 bispecific antibody approved global...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongxin Li, Wen Zhao, Chengming Li, Hongchang Shen, Meiying Li, Chengjun Wang, Chunyan Han, Cuihua Yi, Jun Wang, Xue Meng, Lian Liu, Shuwen Yu, Jisheng Li
Format: Article
Language:English
Published: Wiley 2024-11-01
Series:Thoracic Cancer
Subjects:
bispecific antibody
cadonilimab
CTLA‐4
non‐small cell lung cancer
PD‐1
Online Access:https://doi.org/10.1111/1759-7714.15455
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1111/1759-7714.15455

Similar Items